77858-21-0 Usage
Originator
Velaresol ,Wellcome (GSK)
Manufacturing Process
1st method of preparation of 5-(2-formyl-3-hydroxyphenoxy) pentanoic acid:
(A) 5-(2-Formyl-3-methoxyphenoxy)pentanoic acid:
2-Hydroxy-6-methoxybenzaldehyde (16.875 g, 0.111 M), ethyl 5-
bromopentanoate (23.25 g, 17.6 ml, 0.111 M), anhydrous potassium
carbonate (16.5 g), sodium iodide (0.675 g) and 95% ethanol (150 ml) were
refluxed with stirring (16 hours). The cooled reaction mixture was filtered and
the solid washed well with ethanol. The filtrate was evaporated to dryness and
the residue partitioned between ether and water. The ethereal layer was
separated and washed with 2 N sodium hydroxide solution, water, dried
(sodium sulfate) and evaporated. The residue was dissolved in 95% ethanol
(300 ml) and 0.66 N sodium hydroxide solution (450 ml) and stirred at
ambient temperature (4 hours). The reaction mixture was evaporated to half
volume and diluted with water. The mixture was extracted once with ether and
the aqueous layer acidified with concentrated hydrochloric acid with cooling.
The crystalline solid formed was filtered off and washed well with water.
Recrystallisation from ethyl acetate-petrol gave 5-(2-formyl-3-
methoxyphenoxy)pentanoic acid, melting point 99-101°C.(B) 5-(2-Formyl-3-hydroxyphenoxy)pentanoic acid:
5-(2-Formyl-3-methoxyphenoxy)pentanoic acid (504 mg, 0.002 M) was
dissolved in anhydrous dichloromethane (20 ml) and cooled to -70°C. A
solution of boron trichloride in anhydrous dichloromethane (0.25 g/ml, 3.76
ml) was added dropwise over 10 min and the mixture stirred at -70°C (15
min). The reaction mixture was allowed to reach ambient temperature and
stirred at that temperature (1.25 hours). After cooling to 10°C, 10% sodium
acetate solution (15 ml) was added dropwise with stirring so that the
temperature did not rise above 15°C. The resulting mixture was diluted with
ethyl acetate (50 ml) and filtered. The filtrate was transferred to a separating
funnel and the aqueous layer separated. The organic phase was extracted with
10% sodium carbonate solution (2 x 50 ml), the combined extracts acidified
with concentrated hydrochloric acid and extracted with ethyl acetate. The
combined extracts were washed with water, dried (sodium sulfate) and
evaporated to give a crystalline solid. This solid was dissolved in the minimum
of chloroform-methanol (95:5) and passed through a pad of Kieselgel G.
Evaporation of the filtrate and recrystallization from benzene-petrol gave 5-(2-
formyl-3-hydroxyphenoxy)pentanoic acid, melting point 97-99°C.
2nd method of preparation of 5-(2-formyl-3-hydroxyphenoxy)pentanoic acid:
(A) Ethyl 5-(2-formyl-3-benzyloxypheoxy)pentanoate:A mixture of 2-hydroxy-6-benzyloxybenzaldehyde (3.0 g, 0.013 M), ethyl 5-
bromopentanoate (2.75 g, 0.013 M), anhydrous potassium carbonate (2.16 g,
0.0156 M), sodium iodide (0.195 g) and dry dimethylformamide (15 ml) were
stirred at 60-80°C for 3 hours and then left to stir at room temperature
overnight. The mixture was then poured into water (50 ml) and the product
extracted with ether (2 x 80 ml) and the combined extracts washed with 10%
aqueous sodium hydroxide (2 x 20 ml) and then with water to neutrality,
dried, and evaporated to give ethyl 5-(2-formyl-3-
benzyloxyphenoxy)pentanoate, (4.0 g, 86%) as a pale yellow oil.(B) 5-(2-Formyl-3-benzyloxyphenoxy)pentanoic acid:
A mixture of ethyl 5-(2-formyl-3-benzyloxyphenoxy)pentanoate (3.61 g, 0.01
M), potassium hydroxide (1.19 g, 0.021 M) and ethanol (40 ml) were stirred
at 50°-60°C for 5 hours. The ethanol was then removed in vacuum, the
residue dissolved in water (50 ml) and the solution extracted with ether (2 x
80 ml). The aqueous layer was then acidified by the addition of 2 N aqueous
hydrochloric acid and the product extracted with ether, and the combined
extracts washed with water to neutrality, dried, and concentrated in vacuum
to give 5-(2-formyl-3-benzyloxyphenoxy)pentanoic acid, 3.0 g, 91% as a
yellow oil which crystallized on standing. The crude solid was crystallized from
benzene/petroleum ether to give pale cream crystals, melting point 110°C.(C) 5-(2-Formyl-3-hydroxyphenoxy)pentanoic acid:
A solution of 5-(2-formyl-3-benzyloxyphenoxy)pentanoic acid (1.0 g, 0.003 M)
in ethanol containing 5% palladium on charcoal catalyst (0.61 g) was
hydrogenated at atmospheric pressure. After 20 min the reaction was
complete and the catalyst was filtered off and the ethanol removed in vacuum
to give 5-(2-formyl-3-hydroxyphenoxy)pentanoic acid, m.p. 94°C.3rd method of preparation of 5-(2-formyl-3-hydroxyphenoxy)pentanoic acid:
(A) Ethyl 5-(2-formyl-3-methoxyphenoxy)pentanoate:2-Hydroxy-6-methoxybenzaldehyde (26.0 g, 0.17 M), ethyl 5-
bromopentanoate (27.1 ml, 0.17 M), anhydrous potassium carbonate (25.4
g), sodium iodide (1.04 g) and ethanol (230 ml) were refluxed with stirring
for 16 hours. The cooled reaction mixture was filtered and the solid washed
well with ethanol. The filtrate was evaporated to dryness and the residue
partitioned between ether (200 ml) and water (200 ml). The organic layer was
separated and washed with 2 N sodium hydroxide solution, water, brine, dried
(magnesium sulfate) and evaporated to yield ethyl 5-(2-formyl-3-
methoxyphenoxy)pentanoate 32.97 g, 67% yield, as a pale yellow oil that
solidified on standing in the refrigerator.(B) 5-(2-Formyl-3-hydroxyphenoxy)pentanoic acid:10 ml of a solution of iodine (40.3 g, 0.157 M) in ether (sodium dry, 500 ml)
was added to a stirred mixture of magnesium metal (15.4 g, 0.636 GATOM)
and ether (50 ml). When the reaction had commenced the remainder of the
iodine solution was added dropwise at such a rate as to cause gentle
refluxing. After the addition was complete the reaction mixture was heated to
reflux until a colorless solution was obtained (1/2 hour). The cooled reaction
mixture was filtered and the unreacted magnesium metal was washed with
ether (100 ml). The colorless solution of magnesium iodide thus obtained was
added dropwise to a solution of ethyl 5-(2-formyl-3-
methoxyphenoxy)pentanoate (30.0 g, 0.106 M) in tetrahydrofuran (dried over
molecular sieve, 300 ml) at such a rate as to cause gentle refluxing. A fine
yellow precipitate dropped out of solution. The mixture was brought to reflux
with stirring for 5 hours. The cooled reaction mixture was poured into 10%
hydrochloric acid (400 ml). The organic layer was separated and the aqueous
layer was extracted with ethyl acetate. The combined organic phases,
containing ethyl 5-(2-formyl-3-hydroxyphenoxy)pentanoate, were washed with
water and then extracted into 2 N sodium hydroxide solution. The combined
aqueous extracts were acidified with concentrated hydrochloric acid with ice-
cooling. The precipitate was filtered, washed with water, sucked dry and then
quickly washed with a petrol/ethanol mixture (6:1, 60 ml) to remove some of
the color. The crude product was dried in a desiccator over phosphorus
pentoxide to give a dark-peach colored solid which was then dissolved in ethyl
acetate (250 ml); aluminum oxide (neutral, 10 g) and charcoal (5.0 g) were
added and the mixture stirred vigorously for 1/2 hour and then filtered to give
a pale-yellow solution. The solvent was removed in vacuum to give 5-(2-
formyl-3-hydroxyphenoxy)pentanoic acid, melting point 98-99°C (from ethyl
acetate/petrol).
Therapeutic Function
Antianemic
Check Digit Verification of cas no
The CAS Registry Mumber 77858-21-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,7,8,5 and 8 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 77858-21:
(7*7)+(6*7)+(5*8)+(4*5)+(3*8)+(2*2)+(1*1)=180
180 % 10 = 0
So 77858-21-0 is a valid CAS Registry Number.
InChI:InChI=1/C12H14O5/c13-8-9-10(14)4-3-5-11(9)17-7-2-1-6-12(15)16/h3-5,8,14H,1-2,6-7H2,(H,15,16)
77858-21-0Relevant articles and documents
Compound substituted phenyl phenol ether, intermediate and preparation method thereof
-
Paragraph 0013, (2020/03/17)
. This invention relates to the preparation and application, of the compounds in the preparation of ether compounds, in particular sickle cell anemia, and, to the preparation of such preparations as well as the use of these compounds in human medicine, and to the preparation, of the process and intermediates described in the preparation of ether compounds . The invention further relates to .the use of this compound in the preparation of an ether compound in, the medical field of this invention and the use of .such a preparation.
Pharmaceutical ethers
-
, (2008/06/13)
This invention is directed to novel ether compounds of formula (I) STR1 which are of value in medicine in the palliation of haemoglobinopathies, in particular sickle-cell anaemia, and also in the palliation of pulmonary dysfunction, protection from the effects of hypoxia and the radio-sensitization of tumors. The invention is also directed to methods for the preparation of the ether compounds, to pharmaceutical formulations containing them, the preparation of such formulations and the use of the compounds in human medicine. Also provided by the invention are intermediates of value in the preparation of the ether compounds, by the methods described, and the preparation of the intermediates.
